Clinical Trials Logo

Clinical Trial Summary

This clinical trial focuses on an elaborate, propensity-matched, non-inferiority comparison of NOL-guided Superficial Parasternal Intercostal Plane Block (SPIPB) and Erector Spinae Plane Block (ESPB) within the context of open-heart surgery with cardiopulmonary bypass.


Clinical Trial Description

A. Ethics Local Ethics Committee approval and Informed Consent from patient or next-of-kin are obtained prior to study enrollment. B. Study enrollment Forty consecutive adult patients scheduled for elective open cardiac surgery under general anesthesia are to receive general anesthesia plus SPIPB. This prospective group of patients will be matched one-to-one to a historical group of 55 patients that underwent open cardiac surgery under general anesthesia combined with ESPB. C. Methods C1. Preinduction - 16-G peripheral intravenous cannula and radial artery catheter. - Five-lead ECG, pulse oximetry, non-invasive and invasive blood pressure monitoring. - Analgesia monitor - the NoL index (PMD200TM, Medasense) finger probe will be connected to the index finger of the non-cannulated hand. - Surgical antibiotic prophylaxis (Cefuroxime 1.5g). - Stress ulcer prophylaxis (omeprazole 40 mg). C2. Superficial Parasternal Intercostal Plane Block (SPIPB) After induction, skin asepsis with chlorhexidine 2% is performed on the anterior chest wall. A high-frequency linear ultrasound probe is positioned parasagittally, 2 cm from midline, bilaterally, at the level of the 4th rib. A 25-G echogenic block needle is inserted at a 20⁰-30⁰ angle in a caudal-to-cephalad direction until the tip of the needle reaches the interfascial plane between the pectoralis major muscle and the internal intercostal muscle. Correct hydrodissection is first certified using normal saline. Subsequently, ropivacaine 0.5% with dexamethasone 8mg/20ml is used and maximum spread is attained by slowly advancing the needle as the interfascial plane splits up ahead. A maximum dose of 3mg/kg ropivacaine is used, corresponding to 1.5 mg/kg per side (e.g., 20 ml ropivacaine 0.5% / side for a 70kg adult). C3. General anaesthesia Monitoring - End tidal CO2 (ETCO2). - Bispectral index (BIS) monitoring (target 40-60). - The nociception monitor (PMD200TM, Medasense) is started before induction. - CVP insertion into the right internal jugular vein under ultrasound guidance. - Urinary catheter, rectal temperature probe placement. Induction - Propofol 1-1.5 mg/kg or Etomidate 0.2-0.3 mg/kg. - Fentanyl 5 mcg/kg. - Atracurium 0.5 mg/kg. Maintenance of anaesthesia - Sevoflurane in O2 during periods of preserved pulmonary blood flow and mechanical ventilation. - Propofol infusion during periods of extracorporeal support. - Atracurium 0.2-0.3 mg/kg/h for adequate neuromuscular blockade. Analgesia 1. Analgesic drugs - Fentanyl: bolus 1.5 mcg/kg. - Paracetamol: 1-gram following induction of general anaesthesia. 2. Analgesia monitoring - NoL index provides a multiderivative assessment of nociception before cardiopulmonary bypass (CPB) initiation. Optimal analgesia is defined as a NoL index of 10-25. - Mean arterial blood pressure (MAP) provides post-CPB decision loop: targets are within ± 15% of MAP recorded during optimum NOL. C4. Postoperative Extubation criteria - Normothermia (T◦ ≥ 36◦C). - No clinical bleeding. - Wakefulness. - Hemodynamic stability (MAP ≥ 60 mmHg and lactate ≤ 2 mmol/L) with minimal vasoactive support (dobutamine < 5 µg/kg/min and norepinephrine < 100 ng/kg/min). - Adequate gas exchange: - Tidal volume ≥ 5 ml/kg. - Adequate airway reflex to handle secretions. Analgesia - Paracetamol 1g iv every 6 hours. - Morphine bolus 0.03 mg/kg for NRS > 3. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06070701
Study type Interventional
Source Institutul de Urgenta pentru Boli Cardiovasculare Prof.Dr. C.C. Iliescu
Contact
Status Completed
Phase N/A
Start date June 1, 2023
Completion date April 1, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05534230 - Dexmedetomidine for Pain Reduction in CABG N/A
Recruiting NCT06275698 - HONEY for the Treatment of POst-Tonsillectomy Pain N/A
Recruiting NCT04436224 - Hydromorphone for ICU-analgesia in Patients With Non-mechanical Ventilation Phase 4
Not yet recruiting NCT04548323 - Hypoalgesic Effects of Walking and Running Imagined
Completed NCT06054945 - Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block
Completed NCT04394481 - Extension of Analgesia by Combined Injection of Dexamethasone and Dexmedetomidine After Arthroscopic Shoulder Surgery Phase 4
Completed NCT04690647 - The Efficacy of Suprainguinal Fascia Iliaca Compartment Block for Analgesia After Elective Total Hip Replacement. N/A
Completed NCT05034601 - ESPB vs TPVB for Postoperative Analgesia After the Nuss Procedure N/A
Completed NCT03740815 - Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection N/A
Recruiting NCT05454202 - Assessment of the Interest of ANI in the Non-communicating Patient in Palliative Care
Recruiting NCT04554186 - Serratus Anterior Plane Block Versus Thoracic Paravertebral Block. N/A
Suspended NCT04860635 - Safety of F14 Following Total Knee Replacement Phase 2/Phase 3
Not yet recruiting NCT06393777 - Effectiveness of Pre-administered Natural Sweet-tasting Solution (Honey) for Decreasing Pain of Needle Insertion N/A
Not yet recruiting NCT04519463 - The Effect of Local Anesthesia With Lidocaine During Insertion and Removal of Nasal Packing Early Phase 1
Completed NCT02916342 - Interscalene Block Versus Combined Supraprascapular: Axillary Nerve Blocks Phase 4
Not yet recruiting NCT02549118 - Tenoxicam for Intrapartum Analgesia Phase 2
Completed NCT03206554 - Local Infiltration Analgesia in Total Knee Arthroplasty Phase 2
Not yet recruiting NCT02190760 - Comparison Between Perineural and Systemic Effect of Dexamethasone for Interscalene Brachial Plexus Block. N/A
Completed NCT01789606 - Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet Phase 3
Completed NCT01299584 - ULTIVA Post Marketing Surveillance N/A